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Abstract
Background: Clostridium difficile infection (CDI) is a major health problem. Epidemiological evidence suggests that there is
an association between acid suppression therapy and development of CDI.
Purpose: We sought to systematically review the literature that examined the association between histamine 2 receptor
antagonists (H2RAs) and CDI.
Data source:We searched Medline, Current Contents, Embase, ISI Web of Science and Elsevier Scopus from 1990 to 2012 for
all analytical studies that examined the association between H2RAs and CDI.
Study selection: Two authors independently reviewed the studies for eligibility.
Data extraction: Data about studies characteristics, adjusted effect estimates and quality were extracted.
Data synthesis: Thirty-five observations from 33 eligible studies that included 201834 participants were analyzed. Studies
were performed in 6 countries and nine of them were multicenter. Most studies did not specify the type or duration of
H2RAs therapy. The pooled effect estimate was 1.44, 95% CI (1.22–1.7), I
2 = 70.5%. This association was consistent across
different subgroups (by study design and country) and there was no evidence of publication bias. The pooled effect
estimate for high quality studies was 1.39 (1.15–1.68), I2 = 72.3%. Meta-regression analysis of 10 study-level variables did not
identify sources of heterogeneity. In a speculative analysis, the number needed to harm (NNH) with H2RAs at 14 days after
hospital admission in patients receiving antibiotics or not was 58, 95% CI (37, 115) and 425, 95% CI (267, 848), respectively.
For the general population, the NNH at 1 year was 4549, 95% CI (2860, 9097).
Conclusion: In this rigorous systematic review and meta-analysis, we observed an association between H2RAs and CDI. The
absolute risk of CDI associated with H2RAs is highest in hospitalized patients receiving antibiotics.
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Introduction
Clostridium difficile infection (CDI) is considered a major health
problem with a point prevalence of 13.1/1000 in-patient [1] and is
increasing in incidence and mortality [2–5]. The CDI cost in the
United States of America (USA) alone was conservatively
estimated to exceed $1.1 billion annually [6]. Risk factors
associated with CDI acquisition are numerous and traditionally
have included exposure to antibiotics, advanced age, comorbid-
ities, enteral feeding, prolonged hospitalization, endoscopy and
antineoplastic medications [7–10].
The role of gastric acid suppression therapy has gained interest
recently as a risk factor for CDI. Four recently published meta-
analyses have suggested an association between gastric acid
suppression therapy with proton pump inhibitors (PPI) and CDI
[11–14]. The United States Food and Drug Administration (FDA)
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recently warned the public about a possible association between
CDI and PPI use [15]. However, to date; there is no systematic
review dedicated to evaluate the potential association between
histamine 2 receptors antagonists (H2RAs) use and risk of CDI.
H2RAs are popular over-the-counter (OTC) drugs worldwide
[16]. Off -label use of H2RAs and substitution for physician care
were reported in 46 % and 34% of the adult consumer,
respectively [15]. Masking serious conditions, missed diagnosis,
and the potential for inappropriate use by patients are concerns
about OTC use of H2RAs [17]. Nonetheless, the implications of
OTC H2RAs use are not yet well defined.
Given the high prevalence of prescription use and OTC use of
H2RAs and the increasing incidence and severity of CDI, we
sought to systematically review the published literature that
examined the association between H2RAs use and development
of CDI following the MOOSE [18] and PRISMA [19] guidelines.
We use the Grades of Recommendation, Assessment, Develop-
ment and Evaluation (GRADE) framework [20] to interpret our
findings.
Methods
Search strategy
The search strategy and subsequent literature searches were
performed by a medical reference librarian (PJE) with 37 years of
experience. The initial strategy was developed in Ovid MEDLINE
(1990 through January 2012), using MeSH (Medical Subject
Headings) controlled vocabulary, and then modified for Ovid
EMBASE (1990 through January 2012). Primary terms were:
enterocolitis, pseudomembranous/ AND the therapeutic agents of
interest: explode omeprazole, explode proton pump inhibitors,
anti-ulcer agents, and explode histamine H2 antagonists (Explode
allows including all of the specific drugs, without having to use all
of the various terms, synonyms, brands and generic names.)
Articles were limited to randomized controlled trials, cohort
studies, and or case-control studies. The same process was used
with Ovid EMBASE with alterations as necessary to accommodate
EMBASE’s more granular subject headings. ISI Web of Science
and Elsevier Scopus use text words: (difficile OR pseudomembra-
nous OR pseudo-membranous) AND (omeprazole OR ‘‘proton
pump’’ OR ranitidine OR h2 OR h-2 OR ‘‘acid suppression’’ OR
antacid*)) AND (random* OR trial* OR blind* OR cohort* OR
controlled OR prospective). Moreover, bibliographic references of
Figure 1. Flow diagram of eligible studies.
doi:10.1371/journal.pone.0056498.g001
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Table 1. Characteristics of the included studies.
Source Country Centers Setting Condition Study Design Inclusion Criteria
Acid Suppression
Therapy
Kutty et al
(VA),262010
US Multicenter Community Gen Pop Case-control Age: $18 yr; Community
onset CDAD
H2RAs: exposure 3mo
prior to test
Kutty et al
(D),26 2010
US Multicenter Community Gen Pop Case-control Age: $18 yr; Community
onset CDAD
H2RAs: exposure
3mo prior to test
Nath et al,
281994
CA Single Hospital Hem-onco pts Case-control Adult; In-patient .3d Acid suppression
therapy
Jayatilaka et al,
27 2007
US Single Hospital Gen In-patient Case-control Age .18 H2RAs: pre
admission
Jayatilaka
et al,272007
US Single Hospital Gen In-patient Case-control Age .18 H2RAs: post
admission
Shah et al
(D),29 2000
UK Single Hospital Gen In-patient Case-control Age .65 yr; Gen medical/
elderly
care wards
H2RAs: upto 16 wk
before diarrhea
Dial et al,
30 2005
UK GPRD Community Gen Pop Case-control Age $18 yr; At least 2 yrs
of records
in the GPR; first
occurrence of CDAD
H2RAs: 90 d prior
to the index date
Debast et al,
31 2009
NL Single Hospital Gen In-patient Case control Age:$18 yr; CDAD H2RAs:
exposure
Lowe et al,
32 2006
CA Single Community Gen Pop Case-control (R) 1 hospital admission for
CDAD; Age $ 66yr; CDAD
diagnosis within 60d
of ABX therapy
H2RAs:
exposure
Dial et al,
33 2006
UK GPRD Community General pop Case-control First prescription oral
Vancomycin; No previous
admission 1yr
before index date
H2RAs: 90d prior
to index date
Aseeri et al,
34 2008
US Single Hospital Gen In-patient Case-control Age $18 Yr; Inpt for $3 d H2RAs: 3d
before CDAD
Dubberke
et al,35 2007
US Single Hospital Gen In-patient Case- Control Pts admitted for .48 hr
between study period
H2RAs
Loo et al,
36 2005
UK Single Hospital Gen In-patient Case-control Hospital Acquired CDAD; H2RAs: 6wk
before diagnosis
Sundram
et al,37 2009
UK Single Hospital Gen In-patient Case-control Adult Hospital
Acquired CDAD
H2RAs: 6wk
prior to onset
Howell
et al,38 2010
US Single Hospital Gen In-patient Cohort Age $18 yr; LOS $3 d;
Only first diagnosis
H2RAs
Dalton et al,
39 2009
CA Multicenter Hospital Med/Surgical
Subspecialty
Cohort, (R) Age: $18 yr; Minimum 7-d
LOS; ABX exposure
H2RAs
Dubberk
et al,402007
US Single Hospital Gen In-patient Cohort, (R) All pts admitted to BJH
for more than 48 hours
H2RAs
Pepin
et al,41 2005
CA Single Hospital Gen In-patient Cohort, (R) Adult In-patient H2RAs
Beaulieu et al,
42 2007
CA Single Hospital Medical ICU Cohort ICU LOS.24hr; Diarrhea
.24 hr and positive
CD toxin
(2d to 2months
post discharge)
H2RAs
Peled et al,
43 2007
IL Single Hospital Gen In-patient Cohort, (P) CD testing during 4m
period; ABX within 40d
prior to diarrhea
H2RAs
Dial et al,
44 2004
CA Single Hospital Med/CT/Surgical
wards
Cohort Pharmacy database; ABX
during study
period; positive toxin in the
infection control registry
H2RAs
Novell et al,
45, 2010
US Single Hospital Gen Inpatients Case-control, (R) Age $18 yr; CDAD H2RAs
Netland et al,
46 2011
US Single Both Gen Pop Cohort, (R) Recurrent CDI H2RAs
H2RAs and Clostridium difficile Infection
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all articles and previous meta-analyses were searched for eligible
studies. We have designed the search strategy to capture any
association between gastric acid suppression therapy and devel-
opment of CDI.
There was no restriction to language. All results were
downloaded into EndNote 7.0 (Thompson ISI Research soft,
Philadelphia, Pennsylvania), a bibliographic database manager,
and duplicate citations were identified and removed. Two authors
(A.B.A. and F.A.) independently assessed the eligibility of identified
studies.
Study selection
To be included, a study had to: (1) be an analytical study; and
(2) examine the association between H2RAs use and incidence of
CDI in adult population.
Data collection
A data collection form was developed and used to retrieve
information on relevant features and results of pertinent studies.
Two reviewers (A.B.A. and F.A.) independently extracted and
recorded data in a predefined checklist. Disagreements among
reviewers were discussed with two other reviewers (I.M.T. and
M.A.A.), and agreement was reached by consensus. We collected
adjusted effect estimates and 95% confidence intervals (CI) based
on the multivariable regression model used in each study.
We used the Newcastle-Ottawa Quality Assessment Scale for
cohort and case-control studies [21] which is intended to rate
selection bias, comparability of the exposed and unexposed groups
of each cohort, outcome assessment, and attrition bias. Two
reviewers (M.A.G and F.A.) independently assessed the method-
ological quality of selected. Disagreement among reviewers was
discussed with 2 other reviewers (I.M.T. and M.A.A.), and
agreement was reached by consensus.
We used the GRADE framework to interpret our findings. The
Cochrane Collaboration has adopted the principles of the
GRADE system [20] for evaluating the quality of evidence for
outcomes reported in systematic reviews.
For purposes of systematic reviews, the GRADE approach
defines the quality of a body of evidence as the extent to which one
can be confident that an estimate of effect or association is close to
the quantity of specific interest. Quality of a body of evidence
involves consideration of within-study risk of bias (methodological
quality), directness of evidence, heterogeneity, precision of effect
estimates and risk of publication bias.
Statistical Analyses
Meta-analyses. The primary effect measures used in the
meta-analysis were Odds Ratios (OR), Hazard Ratios (HR) and
Relative Risks (RR) which were assumed to reasonably estimate
the same association between CDI and H2RAs given the low
Table 1. Cont.
Source Country Centers Setting Condition Study Design Inclusion Criteria
Acid Suppression
Therapy
Jung et al,
47 2010
Korea Single Hospital Gen Inpatients Cohort study, (R) Recurrent CDAD or
treatment failure cases
H2RAs
Loo et al,
48 2011
CA Multicenter Hospital Gen Inpatients Cohort study(P) Age $18, Health Care
Associated CDAD
H2RAs
Manges
et al, 49 2010
CA Single Hospital Gen Inpatients Case control Nosocomial CDAD H2RAs
Kuntz
et a,l50 2011
US Single Community Gen Pop Case control, (R) Community
Associated CDAD
Acid suppression
therapy
Naggie
et al,51 2011
US Multicenter Community Gen Pop Case control Age$18 yr Acid suppression
therapy
Stevens
et al,52, 2011
US Single Hospital Gen Inpatients Cohort, (R) Age $18 yr,
Hospital acquired
H2RAs
Dial et al,
53 2008
CA Multicenter Community Elderly patients Case control Age $65, Community
Associated CDAD
H2RAs
McFarland
et al,54 2007
US Multicenter Both Gen Pop Case control CDAD Diagnosis H2RAs
Kazakova
et al,55 2012
US Single Both Gen Pop Case control CDAD Diagnosis, onset during
the pre-outbreak or outbreak
periods, hospitalization
H2RAs
Modena
et al,56 2005
US Single Both Gen Pop Case control Received at least 5 days
of antibiotics prior to
diagnosis of CDAD
H2RAs
Muto
et al,57 2005
US Single Hospital Gen Inpatients Case control Nosocomial CDAD H2RAs: During the 4
weeks
before detection of
CDAD
Yip et al,
58 2001
CA Single Hospital Gen Inpatients Case control Nosocomial CDAD H2RAs
Abbreviations: US, United States;UK, United Kingdom; BMT, Bone Marrow Transplant; ESRD, End Stage Renal Disease; GPRD – general practice research database; IBD,
Inflammatory Bowel Disease; CD, Clostridium Difficile; CDAD, Clostridium difficile associated diarrhea; LOS, Length of Stay; LTCF, Long Term Care Facility; Gen, General.;
Pop, Population; d, day/days; mo, month/months; yr, year/year; wk, week/week; Pts, Patients; Pt, Patient; Med, Medical; CT, Cardio-thoracic; NL, Netherland; CA, Canada;
IL, Israel; Abd, Abdominal; (P), prospective; (R), Retrospective.*, Mostly hospital.
doi:10.1371/journal.pone.0056498.t001
H2RAs and Clostridium difficile Infection
PLOS ONE | www.plosone.org 4 March 2013 | Volume 8 | Issue 3 | e56498
Table 2. The Association between H2RAs use and development of Clostridium difficile infection from case-control studies.
Source Case Ascertainment Selection of Controls Sample size Adjusted Effect Estimates
Kutty et al,26
(VA)
Non-formed stool,
Positive CD toxin
Randomly selected
from the same geographical
outpatients territory
Exposed group; cases:
7, controls: 13
Crude OR, 1.8 (0.6–4.8)
Non-exposed group;
cases: 29, controls: 95
Kutty et al,26
(D)
Non-formed stool,
Positive CD toxin
Randomly selected from
the same geographical
outpatients territory
Exposed group; cases:
6, controls: 3
Crude OR, 1.3 (0.3–5.6)
Non-exposed group;
cases: 67, controls: 45
Sundram
et al,37 2009
Diarrhea, Positive stool
for CD toxin, ribotyped
Inpatients, No diarrhea, Never
tested positive for CD
Exposed group; cases:
65, controls: 52
Crude OR for PPI/ H2RAs :
1.7, P 0.456
Non-exposed group;
cases: 32, controls: 45
Jayatilaka
et al,27 2007
Diarrhea, Positive toxin Age and sex matched,
Same period of time
H2RAs use pre and
during admission
H2RAs use pre and
during admission
Exposed group; cases:
9, controls: 17
OR: 0.95
(0.39-2.34)
Non-exposed group;
cases: 6, controls: 14
Jayatilaka
et al,27 2007
Diarrhea, Positive
toxin
Age and sex matched,
Same period of time
H2RAs
use post admission
H2RAs
use post admission
Exposed group; cases:
133, controls: 227
OR: 0.73
(0.26-2.06)
Non-exposed group;
cases: 116, controls: 230
Loo et al,36
2005
Diarrhea/positive CD, Endoscopic
diagnosis, histological evidence
Matched to Age,
Charlson index, date of
admission, ward, LOS
Exposed group; cases:
47, controls: 47
Diarrhea/positive CD, Endoscopic
diagnosis, histological evidence
Non-exposed group;
cases: 190, controls: 190
Shah et al,29
2000
Diarrhea Positive
stool for CD toxin
Negative stool toxins,
Similar age, Hospital
ward, Same time
Exposed group; cases:
22, controls: 22
Diarrhea
Non-exposed group;
cases: 104, controls: 104
Positive stool
for CD toxin
Dial et al,33
2006
Patients with first prescription
of oral Vancomycin
Age matched,
Same ward
Exposed group; cases:
23, controls: 112
Patients with first prescription
of oral Vancomycin
Non-exposed group;
cases: 294, controls: 2055
Asseri et al,34
2008
Diarrhea Matched to date of
admission, antibiotic use,
gender, age group, patient
location, room type
Exposed group; cases:
17, controls: 9
Diarrhea
Positive stool
for CD toxin
Non-exposed group;
cases: 77, controls: 85
Positive stool
for CD toxin
Dial et al,30
2005
Positive CD toxin Same general practice,
Not hospitalized in the year
prior to index date, Negative
CD toxin, No diagnosis of CDI
Exposed group;
cases: 83, controls: 367
Positive CD toxin
Clinical diagnosis
made by GP
Non-exposed gp;
cases: 1150, controls:
11963
Clinical diagnosis
made by GP
Lowe et al,32
2006
CDAD Matched to age, sex,
and antibiotic use
Exposed group;
cases: 213, controls:
1846
Non-exposed gp;
cases: 1176, controls:
10457
Exposed group; cases: 213, controls:
1846
Non-exposed gp; cases: 1176,
controls: 10457
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Table 2. Cont.
Source Case Ascertainment Selection of Controls Sample size Adjusted Effect Estimates
Debast et al,31
2009
Diarrhea Randomly selected fro
the same time and same
wards as
CDI cases
Exposed group; cases:
2, controls: 2
Exposed group; cases:
2, controls: 2
Positive stool
for CD toxin
Non-exposed group;
cases: 43, controls: 88
Non-exposed group;
cases: 43, controls: 88
Nath et al,28
1994
Diarrhea Age matched,
Same hospital unit
Exposed group; cases:
51, controls: 32
Exposed group; cases:
51, controls: 32
Positive stool
for CD toxin
Non-exposed group;
cases:29, controls: 48
Non-exposed group;
cases:29, controls: 48
Dubberke
et al,35 2007
Diarrhea Randomly selected
During the study period
Exposed group; cases:
206, controls: 426
Exposed group; cases:
206, controls: 426
Positive stool
for CD toxin
Non-exposed group;
cases: 176,
controls: 1102
Non-exposed group;
cases: 176, controls: 1102
Novell et al,45
2010
New diarrhea Matched to in-patient unit,
age, gender, date of admission
Exposed group; cases:
12, controls: 07
Exposed group; cases:
12, controls: 07
Positive stool
for CD toxin
Non-exposed group;
cases: 162,
controls: 167
Non-exposed group;
cases: 162, controls: 167
Manges et al,49
2010
Diarrhea/positive CD, Endoscopic
diagnosis, histological evidence
Matched to Age, gender,
date of hospitalization
Exposed group; cases:
09, controls: 12
Exposed group; cases:
09, controls: 12
Non-exposed group;
cases: 16, controls: 38
Non-exposed group;
cases: 16, controls: 38
Kuntz et al,50
2011
ICD-9 code, CDAD Randomly selected Exposed group; cases:
55, controls: 157
Exposed group; cases:
55, controls: 157
Non-exposed group;
cases: 249,
controls: 2883
Non-exposed group;
cases: 249, controls: 2883
Naggie et al,51
2011
Diarrhea Matched by geographic
location
Exposed group; cases:
22, controls: 44
Exposed group; cases:
22, controls: 44
Positive stool
for CD toxin
Non-exposed group;
cases: 44, controls: 70
Non-exposed group;
cases: 44, controls: 70
Dial et al,53
2008
ICD-9 code
008.45, CDAD
Randomly selected, matched
to index date and date of first
hospital admission
NR RR:1.60 (0.90-2.20)
McFarland
et al,54 2007
Acute diarrhea
Culture positive or positive
C.D toxins
Matched to time of
CDAD, Age, Ward
Exposed group; cases:
24, controls: 160
NR
No other cause
for the diarrhea
Non-exposed group;
cases: 23,
controls: 161
Kazakova
et al,55 2012
Diarrhea, positive
CD toxin A
Matched to Sex, Age,
admission date
Exposed group;
cases:19, controls: 49
OR:2.69
(1.22-5.97)
Non-exposed group;
cases: 18,
controls: 109
Modena
et al,56 2005
Diarrhea Inpatients, Received
antibiotics for at least 5 days
Exposed group;
cases:32, controls:18
NR
Positive stool
for CD toxins
Non-exposed group;
cases: 98,
controls: 102
Muto et al,57
2005
Diarrhea Matched to admission date,
Type of medical service,
Length of hospital stay
Exposed group;
cases:159, controls:44
OR:2.00
(1.10-3.50)
Positive stool
for CD toxin
Non-exposed group;
cases: 141,
controls: 62
Yip et al,58
2001
Diarrhea Matched to Age,
Gender, admission date
Exposed group;
cases:14, controls:13
OR:2.70
(0.71–10.10)
Positive stool
for CD toxin
Non-exposed group;
cases: 9, controls: 18
doi:10.1371/journal.pone.0056498.t002
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incidence of CDI and thus were pooled together. Adjusted effect
estimates were primarily used for this analysis. Unadjusted effect
estimates were used as alternatives if studies did not pursue
adjustment because of absence of association on univariate
comparison.
Effect estimates from all included studies were pooled in a meta-
analysis weighing individual studies according to their log-
transformed inverse variance. The DerSimonian and Laird
random effects model [22] was used to calculate the pooled effect
estimates.
We extracted data on the proportion of CDI cases that were
exposed to antibiotics from all studies that reported these data. We
then performed a meta-analysis for the proportion on logit scale
using random effects model weighing the individual studies
according to their log-transformed inverse variance.
Exploring heterogeneity. Homogeneity among studies was
tested by means of Cochran’s Q test and calculation of the
variation across studies attributable to heterogeneity rather than
chance (I2). The influence of a range of a-priori selected study-level
and aggregated individual-level parameters on the observed effect
Table 3. The Association between H2RAs use and development of Clostridium difficile infection from cohort studies.
Source Case Ascertainment Selection of Controls Sample size
Adjusted Effect
Estimates
Howell et al,38
2010
Positive CD toxin A nearest-neighbor–
matching algorithm
was applied
Exposed group; cases: 66,
controls: 10619
OR : 1.53 (1.12–2.10)
Non-exposed group; cases:599,
controls: 90512
Dalton et al,39
2009
Positive stool toxins or colonoscopy-
confirmed psudomembraneous colitis
Age, $ 18 years, Minimum
7d LOS, Antibiotic exposure
Exposed group; cases:
28 controls: 2135
OR, 1.70 (1.09 2.64)
Non-exposed group;
cases:121, controls: 12435
Dubberk et al,40
2007
Positive stool for CD In-patient, No positive
stool toxin assay during the
period
(60d before start
of study to the end)
Exposed group; cases: 206,
controls: 998 Non-exposed group;
cases: 176, controls: 25716
OR, 2.0 (1.6-2.6)
Pepin et al,
41 2005
Diarrhea, Positive toxin, proven
pseudomembranous colitis
Unclear Exposed group; cases:
1199, controls: NR
HR, 1.07 (0.8-1.43)
Non-exposed gp; cases:
6222, controls: NR
Beaulieu et
al,42 2007
Diarrhea
Positive stool for CD toxin
Unclear Exposed group; cases:
470, controls: NR
HR, 0.78 (0.5 – 1.23)
Non-exposed group;
cases: 357, controls: NR
Peled
et al,43 2007
Diarrhea
Positive stool for CD toxin
Diarrhea with negative
stool for CD, same
institution
Exposed group; cases:
22, controls: 45
OR, 3.1 P value : 0.024
Non-exposed group;
cases: 30, controls: 120
Dial
et al,44 2004
Positive stool
for CD toxins
Unclear Exposed group; cases:
NR, controls: NR
OR : 1.1 (0.4-3.4)
Non-exposed group;
cases: NR, controls: NR
Netland
et al, 46 2011
Diarrhea between 5–60 days
after antibiotic therapy for CDAD
Patients with CDAD in
the same institution
Exposed group; cases:
05, controls: 50
OR, 0.49 P value : 0.33
Non-exposed group;
cases: 50, controls: 99
Jung
et al,47 2010
Diarrhea or pseudomembranous
colitis, Positive toxin
Same institution Exposed group; cases:
06, controls: 31
OR, 1.59 P value :
0.367
Non-exposed group;
cases: 08, controls: 66
Loo
et al,48 2011
Diarrhea and: positive CD, histological evidence
or pseudomembranous colitis
Frequency matching
approach
Exposed group; cases:
NR, controls: NR
OR : 0.55 (0.21 – 1.49)
Non-exposed group;
cases: 190, controls: 190
Stevens
et al,52 2011
Diarrhea Positive
stool for CD toxin
Same institution Exposed group; cases:
23, controls: 1060
HR, 1.7 (0.7 – 3.9), P
value 0.25
Non-exposed group;
cases: 218, controls: 8853
doi:10.1371/journal.pone.0056498.t003
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Table 4. Modified Newcastle-Ottawa quality assessment scale for case-control studies included in the meta-analysis.
Selection* Exposure0
Included
Studies
Adequacy of
Case Definition
Represent-
ativeness
of the Cases
Selection
of Controls
Definition
of Controls
Compara-
bilityN
Ascertainment
of Exposure
Same Method of
Ascertainment
for Cases and
Controls
Non-
Response-
Rate
Total
No.
of stars
Kutty et al,26
2010.
A* A* A* A* A* A* A* C 7
Nath et al,28
1994
A* A* B A* A** A* A* C 7
Jayatilaka et
al,27 2007
B A* B A* A** A* A* C 6
Shah et al,29
2000
A* A* B A* A* A* A* C 6
Lowe et al,32
2006
A* A* A* A* A* A* A* C 7
Dial et al,30
2005
A* A* A* A* A* A** A* C 8
Dial et al,33
2006
B A A* A A* A** A* C 5
Aseeri et al,34
2008
A* A* B A* A** E B* C 6
Dubberke
et al,35 2007
A* B B A* A** A* A* C 6
Loo et al,36
2005
A* A* B A* A* E A* C 5
Sundram
et al,37 2009
A* A* B A* A* A* A* C 6
Novell et al,45
2010
A* A* B A* A** A* A* C 7
Debast et al,31
2009
A* A* B A* A* A* A* C 6
Kuntz et al,50
2011
A* A* A* A* A* A* A* C 7
Manges
et al,49 2010
A* A* B B A* A* A* C 5
Naggie et al,51
2011
A* A* A* A* A* C A* C 6
McFarland
et al,54 2007
B A* C A* A* A* A* C 6
Modena
et al,56 2005
B A* B A* A** A* A* C 5
Muto et al,57
2005
B A* B A* A** A* A* C 6
Yip, et al,58
2001
B A* B A* A** A* A* C 6
Dial et al,53
2008
B A* B A* A* A* A* C 5
Kazakova
et al,55 2006
A* A* B A* A** D A* C 6
*Selection:
(1)Is this case definition adequate? A, yes, with independent validation; B, yes, eg record linkage or based on self reports C, no description.
(2) Representativeness of the cases: A, Consecutive or obviously representative series of cases; B, Potential for selection biases or not stated.
(3) Selection of controls: A, Community controls; B, Hospital controls; C, No description.
(4) Definition of controls: A, No history of disease; B, No description of source.
NComparability: Comparability of cases and controls on the basis of the design or analysis: A, study controls for co-morbidities; B, study controls for any additional factor
(e.g., age and severity of illness).
0Exposure:
Ascertainment of exposure: A, Secured records; B, Structured interview where blind to case/control status; C, Interview not blinded to case/control status; D, written self
report or medical record only.
Same method of ascertainment for cases and controls; A, yes; B, no.
Non-response rate: A, Same for both groups; B, Non-respondents described; C, Rate different and no designation.
doi:10.1371/journal.pone.0056498.t004
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estimate was investigated by means of meta-regressions. In these
analyses, the log odds ratio from each study was regressed on the
potential confounders in univariate and multivariate weighted
linear regressions, weighted according to the inverse standard
error and the residual between-study variance. Ten potential
confounders were considered. Seven variables were categorical:
design of the study (case-control vs. cohort), country of publication,
setting (single center vs. multicenter), method of ascertainment of
antibiotic use, method of effect measure (OR vs. RR/HR), effect
estimate (adjusted vs. unadjusted) and quality of included studies
(high score vs. low score). Three continuous variables were: the
impact factor of the journal where the study was published,
number of variables the effect measure was adjusted for and
proportion of cases that were exposed to antibiotics.
Publication bias. The possible influence of publication bias
was graphically assessed with the novel method of contour-
enhanced funnel plot where log-transformed odds ratios were
plotted against standard errors. This method examines whether
any funnel plot asymmetry is likely to be due to publication bias
compared with other underlying causes of funnel plot asymmetry.
The contours help to indicate whether areas of the plot, where
studies are perceived to be missing, are where studies would have
statistically significant effect sizes or not and thus decrease or
increase the evidence that the asymmetry is due to publication
Figure 2. Forest plot-random effect model meta-analysis of the association between CDI and H2RAs based on 35 observations
stratified by country. Error bars indicate confidence interval.
doi:10.1371/journal.pone.0056498.g002
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bias. The presence of funnel plot asymmetry was also assessed
using Egger’s test [23].
Residual confounding. Finally, the possible influence of
unknown confounders (residual confounding) was investigated
with a rule-out approach described by Schneeweiss [24]. This
approach stipulates the influence of a hypothetical confounder and
determines what characteristics this confounder must have to fully
account for the observed association between use of H2RAs and
occurrence of CDI. The hypothetical confounder is characterized
by its association to H2RAs use (OREC, odds ratio of exposure to
the confounder) and its association to the outcome (RRCO, relative
risk of outcome in individuals exposed to the confounder vs. non-
exposed). For this analysis, the absolute risk in the pooled non-
exposed group was used for conversion of odds ratio to relative risk
using the method described by Zhang and Yu [25]. Separate
analyses were performed to demonstrate what levels of OREC and
RRCO would be required to fully explain the observed association
between H2RAs and CDI for different hypothetical prevalence of
the unknown confounder (i.e. PC= 0.2, PC= 0.4) before and after
adjustment for publication bias as described above.
In all analyses, results associated with p-values ,0.05 (two-sided
test) were considered statistically significant. All statistical analyses
were performed using Stata version 12 statistical software
(StataCorp, College Station, Texas).
Results
Search results
The search yielded 27 eligible studies after excluding 260
citations. Six more studies were retrieved from recent review
articles and added to the total eligible studies. Kutty [26] et al and
Jayatilaka [27] et al, each reported 2 different observations for
Figure 3. Forest plot of the pooled proportion of Clostridium difficile cases that were exposed to antibiotics.
doi:10.1371/journal.pone.0056498.g003
Table 6. Influence of study type and country on the pooled effect estimate and its associated heterogeneity.
Group Pooled Effect Estimate (95 % CI) I2 % Number of Observations
All studies 1.44 (1.22, 1.70) 70.5 35
Case-control studies 1.58 (1.28, 1.95) 68.9 24
Cohort studies 1.19 (0.87, 1.62) 75.6 11
Asia 1.86 (1.07, 3.22) 0 2
Canada 1.25 (0.97, 1.61) 60.8 9
Europe 1.43 (1.09, 1.89) 39.3 7
USA 1.51 (1.16, 1.95) 65.1 17
doi:10.1371/journal.pone.0056498.t006
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different participants. Thus, a total of 33 articles met our inclusion
criteria representing 35 observations that included 201834
participants. There was excellent agreement for the inclusion of
the studies, data abstraction and quality assessment between the
reviewers (kappa statistic being 1.0, 1.0 and 0.91 respectively).
The study selection process is illustrated in Figure 1 and the
main characteristics of the included studies are summarized in
Table 1. Twenty-four case control studies [26–37,45,49–51,53–
58] and 11 cohort studies [38–44,46–48,52] reported data on both
community-acquired and hospital-acquired CDI (8 observations
were from community-acquired CDI, 23 from hospital-acquired
CDI and 4 representing both type of CDI). Six studies
[26,39,47,51,53,54] were from multiple centers; two from UK
general practice research database [28,30], and the remaining
were from single centers. The included studies were performed in
6 countries (17 studies from USA, 9 from Canada, 6 from United
Kingdom, 1 from Netherlands, 1 from Israel, and one from
Korea). Most studies did not specify the type or duration of
therapy with H2RAs. Tables 2 and 3 summarized the case
ascertainment, control or non-exposed group selection method for
case control and cohort studies, respectively. Among all citations,
seventeen studies reported the proportion of cases exposed to
antibiotics. Eight studies used antibiotics exposure as inclusion
criteria. Three studies did not provide either the absolute number
of exposed or unexposed groups thus were not included in this
pooled proportion analysis.
Quality assessment
Quality assessment of all included studies was done using the
validated Newcastle-Ottawa Quality Assessment Scale [21] for
cohort and case control studies (Tables 4 and 5). Included studies
were scored based on the sum number of the stars given to each
study. Among case-control studies, Loo et al 2011, Manges et al
2010, McFarland et al 2007, Modena et al 2005 and Dial et al
2008 scored the lowest. While Beaulieu et al 2005 scored the
lowest among cohort studies. Most studies were of good quality
with no evidence of selection bias, and with good comparability of
the exposed and unexposed groups of each cohort, and outcome
assessment.
Meta-analysis
Thirty-five observations from 33 eligible studies were pooled
using a random effect model meta-analysis. We excluded the study
by Jenkins et al. as an outlier due to its large standard error. The
pooled effect estimate was 1.44, 95% CI (1.22–1.7), I2 = 70.5%.
The pooled effect estimate for high quality studies was 1.39 (1.15–
1.68), I2 = 72.3%.
Although the heterogeneity between the analyzed studies was
moderate, the majority of studies pointed towards a positive
association. Figure 2 shows the forest plot and the pooled effect
estimate for all studies stratified by country. Table 6 summarizes
the pooled estimates and associated heterogeneity across different
subgroups. The pooled proportion of CDI cases that were exposed
to antibiotics was 0.81, 95% CI (0.65–0.91) as shown in Figure 3.
Exploring heterogeneity
The influence of a range of a-priori selected study-level and
aggregated individual-level parameters on the observed effect
estimate was investigated by means of meta-regressions. Table 7
summarizes the meta-regression analyses for all 35 results.
Heterogeneity could not be explained by any of the 10 considered
variables.
Publication bias
Figure 4 displays the contour enhanced funnel plot which
showed no evidence of publication bias. This was confirmed by the
Egger’s test (P= 0.905).
Residual confounding
The results of the residual confounding analysis are presented in
Figure 5. Panel A refers to a confounder with a prevalence of 0.20;
at this prevalence level, a strong confounder causing a two-fold
increased risk of CDI would have to be severely imbalanced
between H2 blockers users and non users (OREC =8.87) in order
to fully account for the observed adjusted RR of 1.40. For a very
common confounder with a prevalence of 0.40, stronger
associations with acid-suppression use and/or CDI would be
needed to explain the observed association between acid-
suppression use and CDI. At this prevalence level, the confounder
would have to be both imbalanced (OREC=5.87) and increase
the CDI risk (2.5-fold) to account for the observed OR, after taking
publication bias into account.
Number needed to harm
The number needed to harm (NNH) was estimated by using the
pooled OR from the meta-analysis [59]. A recent large prospective
hospital cohort [48] reported the incidence of CDI at 14 days after
hospital admission in patients receiving antibiotics or not: which
was 42/1,000 and 5.4/1000, respectively. Based on these reported
baseline risks, the number needed to harm (NNH) was 58, 95% CI
(37, 115) and 425, 95% CI (267, 848), respectively. For the general
population, the NNH at 1 year was 4549, 95% CI (2860, 9097) at
1 year, based on a baseline incidence of CDI of 48/100,000
person-years [60].
Table 7. Meta-regression analysis to explore sources of
heterogeneity.
Univariate Analyses
Study Characteristics Coefficient p-values
Study Design 2.27729 0.137
Low score study .194575 0.389
Country where the study is conducted
United States Reference
Canada 2.1738854 0.431
European countries 2.0849204 0.726
Asian Countries .1809134 0.686
Setting 2.0286546 0.893
No of variables adjusted for .0251339 0.175
Method of measuring effect estimate 2.2540725 0.325
Impact factor of the journal 2.0067289 0.380
Method of ascertainment of antibiotic
Patient chart Reference
Pharmacy record 2.0139199 0.955
Interview .3666586 0.517
Questionnaire .2703275 0.703
Combined .0368821 0.905
Not reported .2469137 0.381
Proportion of antibiotic use 2.0023797 0.588
doi:10.1371/journal.pone.0056498.t007
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Discussion
Findings
In this rigorously conducted systematic review and meta-
analysis, we observed an association between H2RAs use and
development of CDI. Using the GRADE framework, the evidence
supporting this association is considered of moderate quality.
Although evidence from observational studies is considered of
weak quality, we have ruled out a strong effect of an unmeasured
confounder and, therefore, have upgraded its quality to moderate
evidence in favor of this association.
The absolute risk of CDI was highest in hospitalized patients
receiving antibiotics with an estimated NNH of 58 at 2 weeks. In
contrast, the risk was very low (4549) in the general population.
We also observed that, on average, 19% of CDI cases had not
been recently exposed to antibiotics.
These findings add to previous subgroup analyses of a limited
number of H2RA studies performed in a recent systematic review
of the association between PPI and CDI. In this review, Kwok [11]
et al conducted a subgroup analysis of 15 H2RA studies and
reported a pooled effect estimate of 1.50, 95% CI (1.23–1.83).
Similarly, Leonard et al [61] reported in 2007 an analysis based
on 12 studies that showed H2RAs use was also associated with risk
of CDI with a pooled OR 1.40, 95% CI (0.85–2.29).
Biologic plausibility
The pathogenic mechanisms operative in H2RAs therapy
causing an increased risk of CDI acquisition are unclear, because
gastric acid does not kill gastric C. difficile spores. One potential
explanation for the association between CDI and gastric acid
suppression therapies could be that the vegetative form of C.
difficile, which is killed by acid, plays a role in pathogenesis.
Vegetative forms survive on surfaces and could be ingested by
patients [62]. Survival of acid-sensitive vegetative forms in the
stomach could be facilitated by two primary factors: (1)
suppression of gastric acid production by acid-suppressive
medications; and (2) presence of bile salts in gastric contents of
patients on acid-suppressive therapy. Bile salts, which are mainly
found in the small intestine, are present in gastric contents,
particularly among patients with gastro-esophageal reflux disease
(GERD).
The extent of gastric acid suppression could play an important
role in potentiating the risk of infection. Kwok [11] et at compared
the risk of CDI with gastric acid suppression from 15 studies that
reported on estimates of both PPI and H2RAs independently on
their sample of participants and found that PPI is associated with
higher risk of infection in comparison to H2RAs though both
increase the risk.
Implications
Our findings have global implications both on the inappropriate
use of acid-suppression therapy and on the increasing incidence of
CDI.
Given the relatively low NNH (58 patients) needed to cause a
case of CDI in hospitalized patients receiving antibiotics it
becomes necessary to judiciously use H2RAs in these patients. In
addition, reducing the inappropriate use of acid-suppression
Figure 4. Contour-enhanced funnel plot of the association between the estimated effect size and its standard error in all studies
comparing those exposed and unexposed to H2RA displays areas of statistical significance on a funnel plot. Contours represent
conventional ‘‘milestone’’ levels of statistical significance (e.g., ,0.01, ,0.05, ,0.1). This funnel plot is symmetrical as it is not missing studies in the
white area excluding the possibility of publication bias (Egger’s test, p = 0.905).
doi:10.1371/journal.pone.0056498.g004
H2RAs and Clostridium difficile Infection
PLOS ONE | www.plosone.org 13 March 2013 | Volume 8 | Issue 3 | e56498
medications in this patient population could lead to a significant
reduction in the incidence of CDI.
On the other hand, our findings are re-assuring to the public
that H2RAs use in the general population as over-the-counter
medications do not pose significant CDI risk and is associated with
a high NNH.
Strengths
Our study has several important strengths. This review is the
first systematic evaluation dedicated to examine the association
between H2RAs and risk of CDI. It includes a comprehensive, up-
to-date literature search and formal assessment of the methodo-
logical quality of pertinent studies with the largest number of
relevant studies as compared to previous reviews [11,61]. In
addition, our pooled estimates are based on multivariate ORs of
studies adjusting for several important CDI risk factors. We also
performed subgroup analyses and sensitivity analyses that
confirmed the robustness of our main results. There was no
statistical evidence of publication bias and the effect of residual
confounding on the observed association was examined. Finally,
the NNH in different risk groups was calculated to aid physicians
and patients in making a decision to use H2RA or not.
Limitations
Our review has certain limitations. There was moderate
between-study heterogeneity; however, this is often the case in
meta-analyses of large observational studies [63–65]. Moreover
the majority of studies pointed towards a positive association.
There was virtually no qualitative heterogeneity, and subgroup
and sensitivity analyses showed results consistent with the main
analysis. There are many patient level parameters which may have
led to substantial heterogeneity. Nevertheless, investigating these
variables is only possible with individual patient data meta-
analysis.
Conclusions
In this rigorous systematic review and meta-analysis, we
observed an association between H2RAs and CDI. The absolute
risk of CDI associated with H2RAs was highest in hospitalized
patients receiving antibiotics. On the other hand, our findings are
re-assuring that H2RAs use in the general population as over-the-
counter medications do not pose a significant CDI risk.
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